Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD
Business Wire•10/11/2026•10:00 ET
0
Key Highlights
- ➤CIDEB(siRNA) cut liver fat by up to 80% after one administration
- ➤Liver-fat reductions remained durable through 36 weeks
- ➤Regeneron leads Phase 1/2 trial and holds exclusive commercialization rights
- ➤Alnylam eligible for development milestones and tiered royalties up to 20%
- ➤CIDEB(siRNA) improved liver injury markers in MASLD patients
Expert Statements
Pushkal Garg, Chief Research and Development Officer at Alnylam
“The magnitude and durability of the reductions in liver fat observed with CIDEB(siRNA) following a single administration are particularly encouraging and represent an important early signal for the potential of RNAi in treating metabolic liver disease”
Pushkal Garg, Chief Research and Development Officer at Alnylam
“These findings reinforce our conviction that RNAi therapeutics can address a much broader range of diseases than those we treat today.”
Pushkal Garg, Chief Research and Development Officer at Alnylam
“They also demonstrate the value of our partnership model, which allows promising science to advance into new disease areas, reach more patients and create additional opportunities for long-term value.”
Alnylam Collaborator Regeneron Advances CIDEB(siRNA) with Promising First-in-Human Results in Patients with MASLD
Single administration of CIDEB(siRNA) resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks
Get started
Create a free account to read the full story.